Jpmorgan Chase & CO Talaris Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.68 - $3.22 $173,913 - $208,955	-64,893 Reduced 14.32%	388,133 $1.09 Million
Q2 2023 Aug 11, 2023	BUY	$1.78 - $3.2 $773,739 - $1.39 Million	434,685 Added 2370.02%	453,026 $1.38 Million
Q1 2023 May 18, 2023	BUY	$1.09 - $2.09 $19,259 - $36,928	17,669 Added 2629.32%	18,341 $34,000
Q1 2023 May 11, 2023	SELL	$1.09 - $2.09 $14,231 - $27,287	-13,056 Reduced 95.1%	672 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.94 - $1.64 $1,297 - $2,263	-1,380 Reduced 9.13%	13,728 $14,000
Q3 2022 Nov 14, 2022	BUY	$2.3 - $5.03 $3,254 - $7,117	1,415 Added 10.33%	15,108 $40,000
Q2 2022 Aug 11, 2022	SELL	$4.51 - $9.85 $5,109 - $11,160	-1,133 Reduced 7.64%	13,693 $62,000
Q1 2022 May 11, 2022	BUY	$6.89 - $16.56 $21,290 - $51,170	3,090 Added 26.33%	14,826 $146,000
Q4 2021 Feb 10, 2022	BUY	$12.18 - $17.0 $68,841 - $96,084	5,652 Added 92.9%	11,736 $179,000
Q3 2021 Nov 12, 2021	BUY	$11.61 - $15.99 $70,635 - $97,283	6,084 New	6,084 $82,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.